Following the decision of Health Canada to withdraw the drug Catena® (idebenone) in Canada, CAFA has prepared two documents to communicate to Health Canada the reaction of people with Friedreich’s ataxia to this decision and its support of the demand to make Catena® (Idebenone) available through a special access program. The testimony form about the effects of Catena® (idebenone) and an official letter from CAFA are available in the Downloads section.

Once the form is completed, you can send it, along with the other letter, directly to Health Canada or send it to us by e-mail: ataxie@lacaf.org. The more we are, the more impact we’ll have!